Influenza [strains A + B] (bivalent) vaccine is under clinical development by BioNTech and currently in Phase II for Influenzavirus A Infections. According to GlobalData, Phase II drugs for Influenzavirus A Infections have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Influenza [strains A + B] (bivalent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Influenza [strains A + B] (bivalent) vaccine overview
Vaccine is under development for the prevention of influenza virus type A and type B infections. The therapeutic is a bivalent modified RNA (modRNA) vaccine. It is administered through intramuscular route.
BioNTech is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, influenza and covid-19. BioNTech utilizes FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Eli Lilly and Co, Genmab AS, and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.
For a complete picture of Influenza [strains A + B] (bivalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.